Table 1.
Demographical and biomarker data of all three cohorts included in this study
| MSA | PD | HC | p value | |
|---|---|---|---|---|
| Total number (n) | 47 | 24 | 25 | |
| Sex (female vs. male) | 16 vs. 31 | 12 vs. 12 | 11 vs. 14 | p = 0.41 |
| Age (y) | 59.9 ± 7.8 | 59.7 ± 8.7 | 62.4 ± 9.2 | p = 0.14 |
| Disease duration (y) | 4.0 ± 1.9 | 4.4 ± 3.3 | – | p = 0.70 |
| Age at first symptom onset | 56.1 ± 9.1 | 55.3 ± 8.0 | – | p = 0.91 |
| MSA-C vs. MSA-P | 25 vs. 22 | – | – | |
| Probable vs. possible MSA1 | 32 vs. 15 | – | – | |
| UMSARS I + II (baseline) | 43.8 ± 13.9 | – | – | |
| MDS-UPDRS III (baseline) | 43.1 ± 17.8 | 25.1 ± 12.2 | – | p < 0.001 |
| Patients with available follow-up data (n) | 18 | – | – | |
| Change in UMSARS I + II over 12-month follow-up | 11.3 ± 12.2 | – | – | |
| Biomarkers | ||||
| Blood samples (n) | 47 | 23 | 21 | |
| Plasma/serum samples (n) | 34/132 | 23/0 | 21/0 | |
| GFAP [pg/ml] | 111.8 ± 61.6 | 93.9 ± 50.1 | 102.1 ± 78.2 | p = 0.45 |
| NfL [pg/ml] | 24.3 ± 8.8 | 10.9 ± 9.0 | 11.4 ± 4.8 | p < 0.0001#.† |
| CSF samples (n) | 15 | 14 | 14 | |
| GFAP [pg/ml] | 17,904.7 ± 6704.3 | 13,885.0 ± 5074.4 | 9495.0 ± 5676.1 | p < 0.01# |
| NfL [pg/ml] | 4580.1 ± 2254.2 | 748.1 ± 350.8 | 703.4 ± 262.2 | p < 0.0001#.† |
| CSF samples with matched plasma samples (n) | 15 | 13 | 10 |
Mean values ± SD. 1According to Gilman criteria. 2For serum samples, corresponding plasma levels were calculated using a transformation equation based on matched serum and plasma samples (see Supplement S1)
†MSA vs. PD
#MSA vs. HC